Breast Cancer Clinical Trial
A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer
Summary
The main purpose of this study is to evaluate the safety and efficacy of abemaciclib in combination with pembrolizumab in participants with advanced non-small cell lung cancer (NSCLC) or hormone receptor positive (HR+), human epidermal growth factor receptor negative (HER2-) breast cancer.
Eligibility Criteria
Inclusion Criteria:
Have a Stage IV diagnosis of 1 of the following: Part A: NSCLC (Kirsten rat sarcoma mutant [KRAS mt], PD-L1+); Part B: NSCLC (squamous histology); Part C: metastatic breast cancer (HR+, HER2-); or Part D: locally advanced or metastatic breast cancer (HR+, HER2-)
Part A: must be chemotherapy naïve for metastatic NSCLC
Part B: must have received at least 1 prior therapy containing platinum-based chemotherapy for advanced/metastatic NSCLC
Part C: must have previously received prior treatment with at least 1 but no more than 2 chemotherapy regimens in the metastatic setting
Part D: cannot have received endocrine therapy or chemotherapy as treatment in the locoregionally recurrent or metastatic breast cancer disease setting. Note: Participants may be enrolled if they received prior (neo)adjuvant chemotherapy or endocrine therapy for localized disease.
Are amenable to provide tumor tissue prior to treatment and provide tumor tissue after treatment initiation (both mandatory).
Have presence of measurable disease as defined by Response Evaluation Criteria in Solid Tumors (RECIST 1.1).
Have a performance status (PS) ≤1 on the Eastern Cooperative Oncology Group (ECOG) scale.
Have discontinued all previous treatments for cancer and recovered from the acute effects of therapy.
Have an estimated life expectancy of ≥12 weeks.
For Part D: Have postmenopausal status due to surgical/natural menopause or chemical ovarian suppression (initiated 28 days prior to Day 1 of Cycle 1) with a gonadotropin-releasing hormone (GnRH) agonist such as goserelin or radiation-induced ovarian suppression.
Exclusion Criteria:
Have a personal history of any of the following conditions: syncope of either unexplained or cardiovascular etiology, ventricular arrhythmia (including but not limited to ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest. Exception: subjects with controlled atrial fibrillation for >30 days prior to study treatment are eligible.
Have central nervous system (CNS) metastasis with development of associated neurological changes 14 days prior to receiving study drug.
Have corrected QT interval of >470 milliseconds on screening electrocardiogram (ECG).
Have history of interstitial lung disease or pneumonitis.
Have history of or active autoimmune disease, or other syndrome that requires systemic steroids or autoimmune agents for the past 2 years.
Have received a live vaccination within 30 days of study start.
Have received prior treatment with an anti PD-1, anti-programmed death ligand 1 (PD-L1), or anti cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) agent.
For Part D Only:
Have initiated bisphosphonates or approved RANK ligand (RANK-L) targeted agents (for example, denosumab) <7 days prior to Cycle 1 Day 1.
Are currently receiving or have previously received endocrine therapy for locoregionally recurrent or metastatic breast cancer. Note: A participant may be enrolled if she received prior (neo)adjuvant endocrine therapy (including, but not limited to anti-estrogens or aromatase inhibitors) for localized disease.
Are currently receiving or have previously received chemotherapy for locoregionally recurrent or metastatic breast cancer. Note: Participants may be enrolled if they received prior (neo)adjuvant chemotherapy for localized disease.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 23 Locations for this study
Fayetteville Arkansas, 72703, United States
San Francisco California, 94158, United States
Aurora Colorado, 80045, United States
Boston Massachusetts, 02215, United States
Detroit Michigan, 48201, United States
New York New York, 10065, United States
Leuven , 3000, Belgium
Liege , 4000, Belgium
Lille Cedex , 59020, France
Montpellier Cedex 5 , 34295, France
Toulouse , 31059, France
Meldola Forli, 47014, Italy
Milano , 20132, Italy
Avila , 05004, Spain
Caceres , 10003, Spain
Madrid , 28041, Spain
Madrid , 28050, Spain
Neihu Taipei , 11490, Taiwan
New Taipei City , 235, Taiwan
Tainan , 73657, Taiwan
Taipei , 10048, Taiwan
Istanbul , 34098, Turkey
Izmir , 35100, Turkey
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.